Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, PhD, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, MS, David Yamauchi, MD, Erasmus Kofi Poku, PharmD, Van Eric Biglang-awa, PharmD, John E. Shively, PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-141114

Published: 2020

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

64 cu-DOTA-Anti-CD33 PET-CT Imaging for Acute Myeloid Leukemia and Image-Guided Treatment

Srideshikan Sargur Madabushi, PhD, Darren Zuro, Jamison Brooks, B.S, Bijender Kumar, PhD, Liliana E Parra, Marvin Orellana, B.S, Indu Nair, PhD, Junie Chea, Kofi Poku, PharmD, Ching-Cheng Chen, PhD, James Sanchez, PhD, John E. Shively, Daniel A. Vallera, PhD, Jeffrey Wong, MD, Anthony S. Stein, MD, David Colcher, PhD, Paul Yazaki, PhD, Susanta Hui, PhD, DABR.

Blood (2018) 132 (Supplement 1): 2747.

https://doi.org/10.1182/blood-2018-99-117878

Published: 2018

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, David Yamauchi, MD, Kofi Poku, PharmD, Van Biglang-awa, PharmD, John E. Shively

Blood (2018) 132 (Supplement 1): 611.

https://doi.org/10.1182/blood-2018-99-116907

Published: 2018

Journal Articles

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Ryotaro Nakamura, Robert Chen, MD, Joycelynne Palmer, PhD, Karl Gaal, MD, Auayporn Nademanee, MD, Leslie Popplewell, MD, James E. Talmadge, PhD, Stephen Gillies, PhD, David Colcher, PhD, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2013) 122 (21): 1808.

https://doi.org/10.1182/blood.V122.21.1808.1808

Published: 2013

Journal Articles

An Engineered Cell Surface Polypeptide for Selection, Tracking and Ablation of Genetically Modified Hematopoietically Derived Cells Based on Human EGFR.

Xiuli Wang, MD, PhD, Wen-Chung Chang, MS, ChingLam W Wong, BS, David Colcher, PhD, Mark Sherman, PhD, Julie R Ostberg, PhD, Stanley R. Riddell, MD, Stephen Forman, MD, Michael C Jensen, MD

Blood (2010) 116 (21): 1469.

https://doi.org/10.1182/blood.V116.21.1469.1469

Published: 2010

Journal Articles

Preclinical Results of the Camptothecin-Polymer Conjugate IT-101 in Multiple Human Lymphoma Xenografts.

Tontanai Numbenjapon, MD, Jianyi Wang, MD, David Colcher, PhD, Thomas Schluep, ScD, Mark E. Davis, PhD, Julienne Duringer, BS, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2007) 110 (11): 1376.

https://doi.org/10.1182/blood.V110.11.1376.1376

Published: 2007

Journal Articles

Preclinical Efficacy of Campthothecin-Polymer Conjugate (IT-101) in Human Burkitt Lymphoma Bearing Mice.

Tontanai Numbenjapon, MD, Jianyi Wang, MD, David Colcher, PhD, Thomas Schluep, ScD, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2006) 108 (11): 2489.

https://doi.org/10.1182/blood.V108.11.2489.2489

Published: 2006

Journal Articles

CD30 as Target for Radioimmunotherapy (RIT) of Lymphoma.

Jan O. Staak, MD, David Colcher, PhD, Satoshi Nagata, PhD, Jianyi Wang, Ira H. Pastan, MD, Andrew A. Raubitschek, MD

Blood (2005) 106 (11): 1501.

https://doi.org/10.1182/blood.V106.11.1501.1501

Published: 2005

Journal Articles

Radiolabeled IL-2-Human Serum Albumin Fusion Protein (Albuleukin™) as a Potential New Reagent for Radioimmunoimaging / Therapy of Hodgkin’s Lymphoma.

Jan O. Staak, MD, David Colcher, PhD, Jianyi Wang, Cynthia Sung, Andrew A. Raubitschek, MD

Blood (2004) 104 (11): 4633.

https://doi.org/10.1182/blood.V104.11.4633.4633

Published: 2004

Journal Articles

The Novel De-Immunized Anti-CD20-IL-2 Immunocytokine DI-Leu16-IL-2 Is Effective in SCID Mice Bearing Rituximab-Resistant Human Lymphoma Xenografts.

Jan O. Staak, MD, David Colcher, PhD, Scott Lauder, Jianyi Wang, Stephen D. Gillies, MD, Andrew A. Raubitschek, MD

Blood (2004) 104 (11): 3288.

https://doi.org/10.1182/blood.V104.11.3288.3288

Published: 2004

NARROW

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

64 cu-DOTA-Anti-CD33 PET-CT Imaging for Acute Myeloid Leukemia and Image-Guided Treatment

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

An Engineered Cell Surface Polypeptide for Selection, Tracking and Ablation of Genetically Modified Hematopoietically Derived Cells Based on Human EGFR.

Preclinical Results of the Camptothecin-Polymer Conjugate IT-101 in Multiple Human Lymphoma Xenografts.

Preclinical Efficacy of Campthothecin-Polymer Conjugate (IT-101) in Human Burkitt Lymphoma Bearing Mice.

CD30 as Target for Radioimmunotherapy (RIT) of Lymphoma.

Radiolabeled IL-2-Human Serum Albumin Fusion Protein (Albuleukin™) as a Potential New Reagent for Radioimmunoimaging / Therapy of Hodgkin’s Lymphoma.

The Novel De-Immunized Anti-CD20-IL-2 Immunocytokine DI-Leu16-IL-2 Is Effective in SCID Mice Bearing Rituximab-Resistant Human Lymphoma Xenografts.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only